- Poster presentation
- Open Access
Non-invasive assessment of liver fibrosis through FibroMeter in patients with chronic viral hepatitis B and C
© Săndulescu et al; licensee BioMed Central Ltd. 2014
- Published: 15 October 2014
- Liver Fibrosis
- Normal Body Mass Index
- Liver Stiffness
- Chronic Viral Hepatitis
- Fibrosis Score
We performed a screening study using FibroMeter (Echosens, Paris) to determine the stage of fibrosis and the necroinflammatory status in a cohort of patients with chronic HBV and HCV infection under surveillance in a tertiary care hospital in Bucharest, Romania.
We analyzed data from 87 patients, 68 (78.2%) of which had chronic HBV infection and 19 (21.8%), chronic HCV infection. The median age was 44.9±15.0 (range 17-75). The mean body mass index (BMI) was 26.0±3.6 in the HBV group and 26.7±3.2 in the HCV group. Overall, 36 patients (41.4%) had normal BMI, another 36 (41.4%) had a BMI equivalent for overweight status, and 15 (17.2%) had grade I obesity.
The distribution of FibroMeter results was: F0-F1: 8 (9.2%), F1: 2 (2.3%), F1-F2: 43 (49.4%), F2: 11 (12.6%), F2-F3: 8 (9.2%), F3: 7 (8.0%), F3-F4: 8 (9.2%). The distribution of the necroinflammatory activity was: A0-A1: 16 (18.4%), A1-A2: 52 (59.8%), A2-A3: 19 (21.8%). We identified no statistically significant differences between patients with HBV and HCV regarding mean fibrosis scores (p=0.476) or mean necroinflammatory activity scores (p=0.681).
The patients included in this study had varied ages and characteristics. FibroMeter classified most of them as F1-F2 but descriptive data should be interpreted in clinical context and potential confounding factors should be identified on a case-by-case basis.
This paper is partially supported by the Sectoral Operational Programme Human Resources Development (SOP HRD), financed from the European Social Fund and by the Romanian Government under the contract numbers POSDRU/159/1.5/S/137390.
- Streinu-Cercel O, Streinu-Cercel A, Preoțescu LL, Streinu-Cercel A: Entecavir as specific antiviral therapy in selected cases of severe acute hepatitis B. GERMS. 2012, 2: 18-22. 10.11599/germs.2012.1009.PubMed CentralView ArticlePubMedGoogle Scholar
- Streinu-Cercel A: Hepatitis C in the interferon-free era. GERMS. 2013, 3: 114-10.11599/germs.2013.1044.PubMed CentralView ArticlePubMedGoogle Scholar
- Poynard T, Munteanu M, Deckmyn O, Ngo Y, Drane F, Castille JM, Housset C, Ratziu V, Imbert-Bismut F: Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population. J Hepatol. 2012, 57: 541-8. 10.1016/j.jhep.2012.04.025.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.